Louisiana State Employees Retirement System Purchases New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Louisiana State Employees Retirement System purchased a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 27,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $790,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of SUPN. SG Americas Securities LLC purchased a new stake in Supernus Pharmaceuticals during the 3rd quarter valued at $800,000. Exchange Traded Concepts LLC raised its holdings in Supernus Pharmaceuticals by 170.7% during the 3rd quarter. Exchange Traded Concepts LLC now owns 41,854 shares of the specialty pharmaceutical company’s stock valued at $1,154,000 after buying an additional 26,390 shares during the period. Campbell Newman Asset Management Inc. raised its holdings in Supernus Pharmaceuticals by 63.7% during the 3rd quarter. Campbell Newman Asset Management Inc. now owns 42,355 shares of the specialty pharmaceutical company’s stock valued at $1,168,000 after buying an additional 16,476 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Supernus Pharmaceuticals by 28.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,949 shares of the specialty pharmaceutical company’s stock valued at $274,000 after buying an additional 2,203 shares during the period. Finally, Assetmark Inc. raised its holdings in Supernus Pharmaceuticals by 2.3% during the 3rd quarter. Assetmark Inc. now owns 28,578 shares of the specialty pharmaceutical company’s stock valued at $788,000 after buying an additional 629 shares during the period.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 14,491 shares of the stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $35.31, for a total transaction of $511,677.21. Following the transaction, the vice president now owns 8,570 shares of the company’s stock, valued at approximately $302,606.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, VP Padmanabh P. Bhatt sold 3,884 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total transaction of $128,133.16. Following the transaction, the vice president now owns 8,570 shares of the company’s stock, valued at approximately $282,724.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Padmanabh P. Bhatt sold 14,491 shares of the stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $35.31, for a total value of $511,677.21. Following the transaction, the vice president now directly owns 8,570 shares in the company, valued at approximately $302,606.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,739 shares of company stock valued at $1,227,433. 8.76% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Piper Sandler reduced their target price on Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 28th.

Supernus Pharmaceuticals Trading Up 2.6 %

SUPN stock opened at $30.07 on Friday. The business’s fifty day simple moving average is $31.51 and its two-hundred day simple moving average is $28.61. Supernus Pharmaceuticals, Inc. has a twelve month low of $21.99 and a twelve month high of $38.09.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.39). Supernus Pharmaceuticals had a return on equity of 0.14% and a net margin of 0.22%. The business had revenue of $164.30 million during the quarter, compared to analysts’ expectations of $155.03 million. During the same quarter in the previous year, the business earned $0.43 EPS. The business’s revenue for the quarter was down 1.8% on a year-over-year basis. Analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.16 EPS for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.